Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, has initiated the commercial manufacturing of Gimoti (metoclopramide) nasal spray with its manufacturing partner, Patheon, a division of Thermo Fisher Scientific. Gimoti was approved by the U.S. FDA on June 19, 2020 for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The company plans to launch sales of Gimoti in the fourth quarter 2020 with its partner Eversana.
 
“We have continued to accelerate the necessary pre-commercialization activities for Gimoti alongside our commercial and manufacturing partners,” said David Gonyer, president and chief executive officer, Evoke Pharma. “Together with Patheon, we have initiated manufacturing process for the first commercial batch of Gimoti. We expect these activities to be completed over the next several weeks and ahead of our planned launch in the fourth quarter of 2020.”